MyoKi

MyoKi is a peptide-based solution designed to support muscle health by selectively inhibiting myostatin, a key regulator of muscle atrophy. By targeting this pathway, MyoKi promotes muscle growth and improves functional muscle performance.

• In a clinical study involving 80 sarcopenia patients, MyoKi increased Skeletal Muscle Mass (2.52%), Lean Muscle Mass (2.56%), Grip Strength (5.6–6.2%), and 6-Meter Walk Test performance (12.4%). Biomarker validation showed increased anabolic signals and decreased catabolic markers.

MyoKi’s convenient oral formulation makes it an ideal adjunct therapy to GLP-1 treatments, helping preserve functional muscle mass and mobility. Its efficacy has been validated across genders and age groups, with potential applications in aging populations, active adults and athletes, pediatric muscle development, and companion animals with muscle wasting or mobility loss.